Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of Schering-Plough/Novartis's indacaterol/mometasone will not displace market leader GlaxoSmithKline's Advair/Seretide in the drug treatment market for asthma.

According to the new Pharmacor report entitled Asthma, the launch of the once-daily emerging therapy indacaterol/mometasone-estimated to achieve blockbuster status in 2016-will not displace Advair/Seretide, the current market leader, which generated sales of more than $3 billion in 2006 in the world's major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). Despite the future blockbuster status of several drugs, the increased cost-consciousness in many markets combined with the impending arrival of multiple lower-priced emerging therapies will result in only modest annual growth in the asthma market from 2006 to 2011, and a small decline in its growth between 2011 and 2016.

The report also finds that the emerging biologic agents Amgen/Wyeth/Takeda's Enbrel, Centocor/Schering-Plough/Tanabe/Janssen Pharmaceuticals' golimumab, Abbott/Eisai's Humira, and PDL BioPharma's Zenapax will generate $785 million in sales in 2016.

"These high-priced emerging biologics will generate significant major market sales despite the small eligible patient population that will receive such agents-severe asthmatics who do not respond to conventional therapy," said Madhuri Borde, Ph.D., analyst at Decision Resources.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563  

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Quality Initiatives & Cost-Sharing Increases as Detroit Healthcare Industry Adjusts To Cuts in the Automobile Industry

View Now